SCHEMBL6415940

SCHEMBL6415940

Cc1cccc(Nc2nc3nonc3nc2NN=Cc2c[nH]nc2-c2ccccc2)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.55
TP53 P04637 4/20 0.50
MAPT P10636 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CDKN1A P38936 1/20 0.44
LMNA P02545 2/20 0.36
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
CFTR P13569 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415936 1.00 BIRC5 (0.55) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL6511740 0.81 CASP3 (0.39) TP53MAPTSMN1; SMN2LMNAPKM
SCHEMBL6511730 0.81 CASP3 (0.39) TP53MAPTSMN1; SMN2LMNAPKM
SCHEMBL6451289 0.78 MAPT (0.52) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL21610034 0.78 MAPT (0.52) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL13905878 0.76 BIRC5 (0.52) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL8265004 0.75 GAA (0.56) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL26030540 0.74 MAPT (0.51) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL6422164 0.74 MAPT (0.51) BIRC5TP53MAPTSMN1; SMN2CDKN1A
SCHEMBL6422161 0.74 MAPT (0.51) BIRC5TP53MAPTSMN1; SMN2CDKN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885TP53 4485/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.